Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Praveen Tipirneni is a distinguished leader in the biopharmaceutical industry, currently serving as the President and Chief Executive Officer of Morphic Therapeutic. With a unique and powerful combination of medical and business expertise, he has successfully guided Morphic in its mission to develop a new generation of oral integrin therapies. Dr. Tipirneni began his career as a physician after earning his M.D., later transitioning into the financial sector as an equity research analyst. He then built an impressive track record in corporate development and strategy at major companies like MedImmune/AstraZeneca and Cubist Pharmaceuticals before taking the helm at Morphic in 2016. His leadership is characterized by a deep scientific understanding and a strategic vision for bringing innovative treatments to patients.
Praveen Tipirneni's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:
As President and CEO, he successfully led Morphic Therapeutic through a period of significant growth, culminating in a successful Initial Public Offering (IPO) on the NASDAQ (MORF) in 2019. He continues to oversee the clinical advancement of the company's promising pipeline of oral integrin inhibitors.
During his time as SVP of Corporate Development at Cubist Pharmaceuticals, he was instrumental in executing key M&A and licensing deals, including the strategic acquisitions of Trius Therapeutics and Optimer Pharmaceuticals, which substantially strengthened Cubist's portfolio prior to its own acquisition by Merck.
Successfully leveraged his dual background, holding an M.D. from the University of Miami and an M.B.A. from the Wharton School, to transition from a medical doctor to a key executive in the biopharma industry, excelling in roles across finance, business development, and corporate leadership.
The Wharton School - Year 1998
McGill University - Year 1991
Massachusetts Institute of Technology - Year 1986
Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Morphic Therapeutic is a clinical-stage biopharmaceutical company dedicated to developing a new generation of oral small-molecule medicines that target integrins. Integrins are a family of proteins that play a critical role in cell-to-cell and cell-to-matrix interactions, implicated in a wide range of diseases. By leveraging its proprietary MInT Platform, the company aims to create highly selective, orally-administered integrin inhibitors to treat serious chronic conditions, including autoimmune, cardiovascular, and fibrotic diseases, offering a more convenient alternative to injectable biologic therapies.
Get verified emails, phone numbers, and LinkedIn profile details
Discover contacts with similar roles, seniority, or companies
Uncover insights like skills, work history, social links, and more
Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.
Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.
Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.
Thousands of companies, including, are just a search away.